Form 4 for KYNB KYNTRA BIO, INC.
Accepted 2024-02-23 00:00:00 ET · period of report 2024-02-21 · accession 0001415889-24-005156 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-23 | 2024-02-21 | KYNB | Wettig Thane | CEO | A - Grant | $0.00 | +166.0K | 423.9K | +64% | $0 |
| D | 2024-02-23 | 2024-02-21 | KYNB | Wettig Thane | CEO | A - Grant | $0.00 | +834.0K | 834.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-21 | A | A | 166,000 | $0.00 | 423,932 | D | — | — | (F1) Represents the grant of restricted stock units (RSUs). Twenty-five percent of the RSUs will vest on March 6, 2025, and the remainder of the RSUs will vest in equal amounts quarterly thereafter for the following three years. |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-02-21 | A | A | 834,000 | $0.00 | 834,000 | D | $1.72 · — to 2034-02-20 | 834,000 Common Stock | (F2) Twenty-five percent of the shares subject to the option will vest on March 1, 2025, and the remainder of the options will vest in equal amounts quarterly thereafter for the following three years. |